Maternal TGF-β ligand Panda breaks the radial symmetry of the sea urchin embryo by antagonizing the Nodal type II receptor ACVRII

PLoS Biol. 2024 Jun 24;22(6):e3002701. doi: 10.1371/journal.pbio.3002701. eCollection 2024 Jun.

Abstract

In the highly regulative embryo of the sea urchin Paracentrotus lividus, establishment of the dorsal-ventral (D/V) axis critically depends on the zygotic expression of the TGF-β nodal in the ventral ectoderm. nodal expression is first induced ubiquitously in the 32-cell embryo and becomes progressively restricted to the presumptive ventral ectoderm by the early blastula stage. This early spatial restriction of nodal expression is independent of Lefty, and instead relies on the activity of Panda, a maternally expressed TGF-β ligand related to Lefty and Inhibins, which is required maternally for D/V axis specification. However, the mechanism by which Panda restricts the early nodal expression has remained enigmatic and it is not known if Panda works like a BMP ligand by opposing Nodal and antagonizing Smad2/3 signaling, or if it works like Lefty by sequestering an essential component of the Nodal signaling pathway. In this study, we report that Panda functions as an antagonist of the TGF-β type II receptor ACVRII (Activin receptor type II), which is the only type II receptor for Nodal signaling in the sea urchin and is also a type II receptor for BMP ligands. Inhibiting translation of acvrII mRNA disrupted D/V patterning across all 3 germ layers and caused acvrII morphants to develop with a typical Nodal loss-of-function phenotype. In contrast, embryos overexpressing acvrII displayed strong ectopic Smad1/5/8 signaling at blastula stages and developed as dorsalized larvae, a phenotype very similar to that caused by over activation of BMP signaling. Remarkably, embryos co-injected with acvrII mRNA and panda mRNA did not show ectopic Smad1/5/8 signaling and developed with a largely normal dorsal-ventral polarity. Furthermore, using an axis induction assay, we found that Panda blocks the ability of ACVRII to orient the D/V axis when overexpressed locally. Using co-immunoprecipitation, we showed that Panda physically interacts with ACVRII, as well as with the Nodal co-receptor Cripto, and with TBR3 (Betaglycan), which is a non-signaling receptor for Inhibins in mammals. At the molecular level, we have traced back the antagonistic activity of Panda to the presence of a single proline residue, conserved with all the Lefty factors, in the ACVRII binding motif of Panda, instead of a serine as in most of TGF-β ligands. Conversion of this proline to a serine converted Panda from an antagonist that opposed Nodal signaling and promoted dorsalization to an agonist that promoted Nodal signaling and triggered ventralization when overexpressed. Finally, using phylogenomics, we analyzed the emergence of the agonist and antagonist form of Panda in the course of evolution. Our data are consistent with the idea that the presence of a serine at that position, like in most TGF-β, was the ancestral condition and that the initial function of Panda was possibly in promoting and not in antagonizing Nodal signaling. These results highlight the existence of key functional and structural elements conserved between Panda and Lefty, allow to draw an intriguing parallel between sea urchin Panda and mammalian Inhibin α and raise the unexpected possibility that the original function of Panda may have been in activation of the Nodal pathway rather than in its inhibition.

MeSH terms

  • Activin Receptors, Type II* / genetics
  • Activin Receptors, Type II* / metabolism
  • Animals
  • Body Patterning* / genetics
  • Embryo, Nonmammalian* / metabolism
  • Gene Expression Regulation, Developmental*
  • Ligands
  • Nodal Protein* / genetics
  • Nodal Protein* / metabolism
  • Paracentrotus* / embryology
  • Paracentrotus* / genetics
  • Paracentrotus* / metabolism
  • Signal Transduction
  • Transforming Growth Factor beta* / metabolism

Substances

  • Transforming Growth Factor beta
  • Activin Receptors, Type II
  • Nodal Protein
  • Ligands
  • activin receptor type II-A

Grants and funding

This research was funded by the Foundation for Medical Research (FRM), (Grant DEQ20180339195 to TL), by the Foundation for Cancer research (ARC) (Grant: ARCPJA32020060002217) to TL, by the Centre National de la Recherche Scientifique (CNRS) to TL, and by a grant from the Agence Nationale de la Recherche (ANR) to TL (ANR-14-CE11-0006-01). PV was supported by a 3-year PhD fellowship from the Foundation for Medical Research (FRM), (Grant DEQ20180339195 to TL) and by a 4th year PhD fellowship from the Ligue nationale contre le cancer. EH was supported by a grant from the Ministère de la Recherche et de l'Enseignement Supérieur and by a 4th year of PhD fellowship from the ARC. MDM was supported by an European Molecular Biology Organization (EMBO) long-term fellowship (grant 1234-2011) and by an ARC postdoctoral fellowship (grant 2011-1204261). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.